Histological and immunohistochemical features and genetic alterations in the malignant progression of giant cell tumor of bone: a possible association with TP53 mutation and loss of H3K27 trimethylation

[1]  T. Shibata,et al.  Base-resolution methylomes of gliomas bearing histone H3.3 mutations reveal a G34 mutant-specific signature shared with bone tumors , 2020, Scientific Reports.

[2]  David C. Jones,et al.  Drivers underpinning the malignant transformation of giant cell tumour of bone , 2020, medRxiv.

[3]  Dylan M. Marchione,et al.  H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone , 2020 .

[4]  Y. Oda,et al.  Histone H3.3 mutation in giant cell tumor of bone: an update in pathology , 2019, Medical Molecular Morphology.

[5]  T. Shibata,et al.  Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone , 2019, Modern Pathology.

[6]  Benjamin A Garcia,et al.  Histone H3K27 Dimethyl Loss is Highly Specific for Malignant Peripheral Nerve Sheath Tumor and Distinguishes True PRC2 Loss from Isolated H3K27 Trimethyl Loss , 2019, Modern Pathology.

[7]  G. Garcia-Manero,et al.  Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide , 2019, Medicine.

[8]  N. Hiraoka,et al.  H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features , 2018, Modern Pathology.

[9]  C. Errani,et al.  Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage , 2018, The Journal of bone and joint surgery. American volume.

[10]  Y. Oda,et al.  Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone. , 2017, Human pathology.

[11]  Sakae Tanaka,et al.  Highly recurrent H3F3A mutations with additional epigenetic regulator alterations in giant cell tumor of bone , 2017, Genes, chromosomes & cancer.

[12]  T. Barth,et al.  H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant , 2017, Histopathology.

[13]  A. Flanagan,et al.  H 3 F 3 A ( Histone 3 . 3 ) G 34 W Immunohistochemistry A Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone , 2017 .

[14]  A. Flanagan,et al.  Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone , 2017 .

[15]  Thomas Wiesner,et al.  Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST , 2016, The American journal of surgical pathology.

[16]  Narasimhan P. Agaram,et al.  Symplastic/pseudoanaplastic giant cell tumor of the bone , 2016, Skeletal Radiology.

[17]  D. Yap,et al.  Weaver Syndrome‐Associated EZH2 Protein Variants Show Impaired Histone Methyltransferase Function In Vitro , 2016, Human mutation.

[18]  A. B. Hassan,et al.  Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast‐rich mimics , 2015, The journal of pathology. Clinical research.

[19]  L. Qin,et al.  PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors , 2014, Nature Genetics.

[20]  M. Stratton,et al.  Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone , 2013, Nature Genetics.

[21]  Tsuyoshi Saito,et al.  p53 mutations may be involved in malignant transformation of giant cell tumor of bone through interaction with GPX1 , 2013, Virchows Archiv.

[22]  David M. Thomas,et al.  Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone , 2012, Clinical Cancer Research.

[23]  M. Péoc'h,et al.  CCND1 and MET genomic amplification during malignant transformation of a giant cell tumor of bone. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  David M. Thomas,et al.  Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. , 2010, The Lancet. Oncology.

[25]  Y. Ishikawa,et al.  Carcinosarcomatous malignancy, osteosarcoma and squamous cell carcinoma, in giant cell tumor of the right distal femur. , 2008, Pathology, research and practice.

[26]  K. Jaskiewicz,et al.  Epithelioid malignant peripheral nerve sheath tumor involving maxillary sinus , 2005, Neuropathology : official journal of the Japanese Society of Neuropathology.

[27]  F. Bertoni,et al.  Malignancy in giant cell tumor of bone , 2003, Cancer.

[28]  Y. Iwamoto,et al.  Secondary malignant giant‐cell tumour of bone: molecular abnormalities of p53 and H‐ras gene correlated with malignant transformation , 2001, Histopathology.

[29]  S. Geary,et al.  Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. , 2001, Bone.

[30]  C. Fletcher,et al.  Expanding the Spectrum of Malignant Change in Schwannomas: Epithelioid Malignant Change, Epithelioid Malignant Peripheral Nerve Sheath Tumor, and Epithelioid Angiosarcoma: A Study of 17 Cases , 2001, The American journal of surgical pathology.

[31]  A. Evdokiou,et al.  Expression of Osteoclast Differentiation Signals by Stromal Elements of Giant Cell Tumors , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[32]  M. Zheng,et al.  Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. , 2000, The American journal of pathology.

[33]  D. C. Henckel,et al.  Case report. , 1995, Journal.

[34]  R. Yesner.  Update in Pathology , 1986 .